FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	ROVAL
OMB Number:	3235-0287
Estimated average	burden

hours per response...

0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	p + e p + e	~)														
1. Name and Address of Reporting Person* EISENBERG JEFFREY F			2. Issuer Name and Ticker or Trading Symbol Xenetic Biosciences, Inc. [XBIO]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X Director 10% Owner								
(Last) (First) (Middle) 40 SPEEN STREET, SUITE 102			3. Date of Earliest Transaction (Month/Day/Year) 03/18/2021					X_ Officer (give title below) Other (specify below) Chief Executive Officer								
(Street) FRAMINGHAM, MA 01701			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person								
(Ci	ty)	(State)	(Zip)			Tab	le I - N	on-Deri	vative Secu	ities Acq	uired,	Disposed o	of, or Benef	icially Owne	i	
(Instr. 3) Date		2. Transaction Date (Month/Day/Year	Execution Date, if Code			(A) or Disposed		d of (D) 5)	Owned Followin Transaction(s) (Instr. 3 and 4)		ecurities Beneficially ng Reported		Ownership Form:	Beneficial Ownership		
					(Code	le V A	mount (E		;				(Instr. 4)		
Reminder:	Report on a	separate line for each	class of securities b	eneficial	lly owned	lirectly		•	s who resp	ond to th	ne col	llection of	informati	on containe	d SEC	1474 (9-02)
Reminder:	Report on a	separate line for each		- Deriva	tive Secui	ities A	i i acquire	Personation this for a current display.	form are no ntly valid O osed of, or B	t require MB cont neficially	ed to r trol nu	respond u umber.		on containe form displa		1474 (9-02)
1. Title of	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date	Table II 3A. Deemed Execution Date, if	- Deriva (e.g., p) 4. Transact Code	5. Nu berive Secur 5. Nu Derive Secur Acqu	mber of ative ities ired (Asposed	acquirecents, opto	Personation this for a current d, Dispositions, co	form are no ntly valid O sed of, or B nvertible sec recisable and Date	neficially urities) 7. Titl of Un Secur	ed to retrol nutrol nut	Amount	8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(f 10. Owners Form of Derivati Security Direct (or Indirects)	11. Natur of Indirec Beneficia Ownershi (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction	Table II 3A. Deemed Execution Date, if any	- Deriva (e.g., p) 4. Transact Code	5. Nu tion Deriv Secur Acqu or Di (D) (Instr	ities A warran mber of ative ities ired (A sposed	cequireents, opt of 6. I Exp (Mo	Persona in this f a curred d, Dispo tions, co Date Exe piration I onth/Day	orm are nontly valid O osed of, or B overtible sec recisable and Date y/Year) Expiration	neficially urities) 7. Titl of Un Secur	od to retrol nutrol nut	Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Owners Form of Derivati Security Direct (or Indir	11. Natur of Indirec Beneficia Ownershi (Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
EISENBERG JEFFREY F 40 SPEEN STREET, SUITE 102 FRAMINGHAM, MA 01701	X		Chief Executive Officer			

Signatures

/s/ Jeffrey F. Eisenberg	03/22/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares underlying the options will vest and become exercisable as follows: one-third of the shares shall vest on the first anniversary of March 18, 2021; the remaining two-thirds of the shares shall vest in eight equal quarterly installments commencing on June 18, 2022 and ending on March 18, 2024.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.